ProPhase Labs (NASDAQ:PRPH – Get Free Report) and Agile Therapeutics (NASDAQ:AGRX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.
Institutional & Insider Ownership
9.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are held by institutional investors. 26.1% of ProPhase Labs shares are held by insiders. Comparatively, 0.5% of Agile Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and target prices for ProPhase Labs and Agile Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProPhase Labs | 0 | 0 | 1 | 0 | 3.00 |
| Agile Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Valuation & Earnings
This table compares ProPhase Labs and Agile Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProPhase Labs | $44.38 million | 2.17 | -$16.78 million | ($0.98) | -5.44 |
| Agile Therapeutics | $19.59 million | 0.13 | -$14.47 million | ($9.84) | -0.04 |
Agile Therapeutics has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
ProPhase Labs has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
Profitability
This table compares ProPhase Labs and Agile Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProPhase Labs | -37.81% | -29.83% | -18.14% |
| Agile Therapeutics | -73.83% | N/A | -179.07% |
Summary
ProPhase Labs beats Agile Therapeutics on 7 of the 12 factors compared between the two stocks.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It also offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
About Agile Therapeutics
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
